We constructed recombinant vaccinia viruses (RVVs) that expressed human T-cell leukemia virus type I (HTLV-I) envelope glycoproteins by using attenuated vaccinia viruses (VVs) which have much lower neurovirulence than the WR strain that is extensively used as a vector. The RVV produced from the LC16mO strain, one of the attenuated VVs, elicited a high titer of anti-HTLV-I antibody in rabbits and protected them against HTLV-I infection. The env gene was inserted into the VV hemagglutinin gene. The resultant inactivation of the hemagglutinin gene led to the attenuation of VVs, but the extent of their attenuation depended on the VV strain. The propagation of LC16mO and its RVV in rabbit brain was poorer than that of LO-1, a cloned derivative of Lister strain, and its RVV, although LC16mO replicated in other organs better than did LO-1. Taken together, these results suggest that LC16mO is a good candidate as a vector for vaccination of humans.
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The use of recombinant vaccinia viruses (RVVs) as live vaccines against a variety of infectious diseases has been proposed (15, 18) . Actually, RVV based on the WR strain has successfully protected vaccinated animals against challenge with pathogenic viruses (4, 5, 14, 17, 19, 23, 25) . However, objections have been raised, primarily concerning the side effects of the VV vector itself, which causes rare but serious complications such as postvaccinal encephalitis and encephalopathy (1) . Although the WR strain has been extensively used in the construction of RVVs, it has never been licensed for use as a vaccine against smallpox. The attenuated VV ought to be a better candidate as a vector, since it presents a lower possibility of the occurrence of side effects.
Lister (Elstree) strain (LO) has been extensively used in Japan for smallpox vaccination. Recently more attenuated strains with temperature sensitivity and lower neurovirulence have been isolated from the LO strain. Among these mutants, the LC16mO strain seems to have promising properties as a vector to express foreign antigens: it grows intradermally just as well as the parental LO strain and it elicits a higher titer of anti-VV antibodies than the LO in spite of its much lower neurovirulence, as shown by intracerebral (i.c.) inoculation in rabbits and monkeys and by its inability to spread into the central nervous system (CNS) via blood in mice inoculated intraperitoneally (i.p.). Furthermore, this strain has been injected into approximatley 10, 000 people in Japan without any reported complications (9) . Thus, LC16mO seems to be a good candidate for a vector to construct RVV. Human T-cell leukemia virus type I (HTLV-I) has been shown to be etiologically associated with human adult T-cell leukemia (ATL) (11, 13, 28 expressing the env gene of HTLV-I have been shown to protect vaccinated rabbits against HTLV-I infection (22) . In the present study we constructed LO-and LC16mO-derived RVVs expressing the env gene and compared their effects against HTLV-I infection. In these constructs the hemagglutinin (HA) gene of VV (20, 21) was used to insert the env gene, and the effects of the disruption of the HA gene on the properties of RVVs were also examined in both the WR and the attenuated strains.
MATERIALS AND METHODS
Cells, viruses, and animals. RK13 and CV-1 cells were grown at 37°C in Eagle minimum essential medium supplemented with 10% fetal calf serum. MT-2 cells were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum. WR, Lister (LO), and LC16mO strains of VV were plaque purified, propagated in RK13 cells, and purified essentially as described by Joklik (12) . The viruses were titrated on monolayers of RK13 cells and evaluated by PFU or 50% tissue culture infectious dose (TCID50). A value of 100 TCID50 corresponds to 70 PFU. To measure plaque formation at high temperature, primary rabbit kidney cells were used. Japan albino rabbits, each weighing 1.8 to 2.3 kg, and 5-week-old male DDY mice were used throughout these experiments.
Construction and isolation of RVVs. Construction of the plasmid that harbors the HTLV-I env gene, placed downstream of the p7.5 promoter and flanked with the segments of the HA gene, has been described previously (22) . The RVVs based on the various strains were isolated as described elsewhere (22) .
Characterization of RVVs in vitro and in vivo. The envelope proteins synthesized by the RVVs were examined by immunofluorescence and immunoprecipitation methods (22) . Immunization of rabbits, quantitation of antibody response, and challenge of immunized rabbits with HTLV-I were done as described previously (22 (6) . Only mice dying between days 2 and 14 after inoculation were used in the calculations.
To evaluate the immunogenicities of VVs, the mice were inoculated i.p. with a virus dose of 105. TCID50. Each mouse was bled at 3 weeks postinfection, and the serum was heat inactivated at 56°C for 30 min. Virus neutralization assays were carried out as described previously (6) . The mice that had a neutralizing antibody titer of >32 were scored as positive, and the seroconversion rate was calculated.
To quantitate the propagation of VVs in liver and spleen, mice were inoculated i.p. with 105 0 TCID50 of strains WR and WR-proenvl and 10' TCID50 of the LO-1 and LC16mO strains and their RVVs. Three mice inoculated with one kind of virus were killed at 4 and 7 days postinoculation, and the virus infectivity of the liver and spleen tissues was quantitated. Growth ability in rabbit skin. To examine the growth ability of virus in the skin, a dermal reaction test was carried out. Serial 10-fold dilutions of virus solutions were prepared with each stock virus, and 0.1 ml of each dilution was inoculated intradermally on the back of a rabbit. Two rabbits were used for one strain, and the solutions containing serial virus dilutions were injected into two places per rabbit. The diameter of erythema formed was measured at 2, 3, 5, 6, and 7 days postinjection. An erythema diameter which exceeded 10 mm was scored as a positive reaction, and virus doses which induced a positive reaction in 50% of the injected area were calculated by the Behrens and Karber method (6) .
Virulence tests in rabbits. Virulence tests were done according to the methods described by Morita et al. (16) . Briefly, to evaluate the neurovirulence of VVs, 0.25 ml of virus solution containing 1068 TICD50 was injected into the right cerebral hemisphere of three or five rabbits. The rabbits were clinically observed for 6 days postinfection.
To recover viruses from the brain, one virus strain was inoculated into six rabbits and three of them were killed at 3 or 6 days postinoculation. The rabbits which showed severe clinical findings were killed before death, and the rabbits that died were autopsied as soon as possible after death. Tissue specimens of the left cerebral hemisphere were collected at autopsy for virus recovery and histological examinations. Ten-percent brain homogenates were prepared in Eagle minimum essential medium containing 10% fetal calf serum, and the viruses present were titrated. For histopathological examination the tissue specimens were fixed in 10% Formalin and embedded in paraffin. Sections were stained with hematoxylin and eosin. The severity of lesions was determined by lesion scores described in Table 6 . The lesion scores were determined by a combination of the severity of choriomeningitis and lesions in the parenchyma and were expressed as the average of three rabbits.
RESULTS
In vitro properties of RVVs harboring the HTLV-I env gene in the HA site. We chose the LC16mO strain as an attenuated VV vector to express HTLV-I env proteins because of the reasons described in the Introduction. LO-1, a cloned derivative of LO, was also tested. The HTLV-I env gene was linked downstream of the VV p7.5 promoter (12) and was then inserted into the middle of the VV HA gene as described previously (22) .
To examine whether the RVVs derived from various parental VVs still retain their original properties in vitro, their plaque size and temperature sensitivity were examined. The WR, LO-1, and LC16mO strains and their RVVs formed plaques of similar sizes at 37°C. Temperature sensitivity of the viruses was investigated at 37 and 40.80C on primary rabbit kidney cells. Strains WR, WR-proenvl, LO-1, and LO-proenv could form a number of plaques at high temperature, although some reduction was detected (Table 1) . On the other hand, both LC16mO and mO-proenv showed marked temperature sensitivity, consistent with the previous report (9) . The yields per cell of each of these RVVs were again similar to those of their parental VVs when the viruses were propagated under the conditions for a one-step growth cycle (Fig. 1) . These results suggest that all the RVVs carrying the env gene in the HA site still retain their parental properties during growth in vitro. To compare the amount of env proteins synthesized in each RVV-infected cell, the infected cells were labeled overnight with [3H]leucine and immunoprecipitated with adult T-cell leukemia sera followed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. All the RVVs directed the synthesis of three envelope proteins, gp62, gp46, and p2OE, which are authentic env proteins (Fig. 2 ) (10, 26) . Although in this gel only one p2OE was apparent, we noticed a doublet in repeated gel electrophoresis, as described previously (22) . Although the amount of the env proteins synthesized varied somewhat among these RVVs, the differences were not the same in repeated experiments, and the amounts of background proteins precipitated nonspecifically were parallel to those of the env proteins, which suggests that the p7.5 promoter worked equally in all the RVV-infected cells and that all the env proteins synthesized were processed properly.
RVV immunization of rabbits and its effect on HTLV-I infection. To examine the immunogenicity of the RVVs and parental VVs, rabbits were intradermally inoculated with each of the purified viruses. Plasma samples were collected at intervals of several weeks postinoculation and were analyzed by the particle agglutination method for titration of anti-HTLV-I antibodies and by the plaque-reduction method for that of anti-VV antibodies. LC16mO-derived RVV induced a quite high titer of anti-HTLV-I antibodies in all animals inoculated, but it was somewhat lower than that of WR-proenvl-induced antibodies (22) . LO-1-derived RVV induced a much lower titer of anti-HTLV-I antibodies (Table  2 ). In summary, the WR-based RVV elicited the highest level of antibodies, the LC16mO RVV elicited a moderate level, and the LO-1 RVV produced the lowest. These results correlated with the mean titers of anti-VV antibodies elicited in rabbits, which suggests that the anti-HTLV-I antibody titer reflects the extent of the growth of each RVV injected intradermally.
Rabbits vaccinated with mO-proenv or LO-proenv were challenged with MT-2 cells and HTLV-I-producing cells, and the appearance of HTLV-I antigen-positive peripheral blood lymphocytes (PBLs) was examined as a sensitive marker of HTLV-I infection (22) . No PBLs possessing HTLV-I antigen were detected in the rabbits vaccinated with mO-proenv by 39 weeks postchallenge, whereas two of the three rabbits immunized with LO-proenv had HTLV-Ipositive PBLs. Thus, the mO-proenv appeared to protect the rabbits from HTLV-I infection, whereas protection by LOproenv (Table 3 ).
In the preceding paper, we found that PBLs of the rabbits vaccinated with WR-proenvl and WR-envl7 had not acquired HTLV-I antigen by 31 weeks postchallenge (22) . These rabbits were kept further, and their PBLs were examined at 4-week intervals until 44 weeks postchallenge so as to confirm the absence of HTLV-I antigen ( Table 3 ). The immunized rabbits were then dissected to determine the presence of the HTLV-I antigen (data not shown). The results further supported the hypothesis that WR-proenvl and WR-envl7 protect rabbits from HTLV-I infection.
Virulence of RVVs made using various W strains in mice. To determine whether RVVs were attenuated owing to inactivation of the VV HA gene by insertion of the env gene, they were inoculated into DDY male mice i.c. and i.p. Table   TABLE 2 
a Rabbit numbering as in our preceding paper (22 infectivity in spleen and liver was directly compared after i.p. inoculation (Fig. 3) . HA-WR-proenvl yielded 102 to 103 times lower levels of infectivity in the spleen and liver tissue than WR. mO-proenv yielded 101 to 102-fold lower infectivity in the spleen than its parental strains; neither virus was detected in the liver. LO-proenv had spleen yields similar to those of LO-1, but neither virus was detected in the liver. Measurement of the VV-neutralizing-antibody level is another indicator to estimate the replication of VVs in mice. At 3 weeks after inoculation with 105.0 TCID50 of the RVVs and VVs, WR-proenvl and HA-WR had significantly lower neutralizing titers than did wild-type WR. On the other hand, LO-1-derived RVV produced anti-VV-antibody titers similar to those of its parental viruses (Table 4 ). All these results, obtained using mice as model animals, indicated that the RVVs produced from LC16mO and LO-1 had lower virulence than those derived from WR, although inactivation of the WR HA gene led to greater attenuation of WR than of LC16mO, and no apparent attenuation of LO-1.
Virulence of various RVVs in rabbits. WR, isolated from a New York City Board of Health strain after multiple passage in mouse brain, has enhanced virulence in mice (2) , whereas it is known that mice are not as sensitive hosts of LO and LC16mO (9) . To ascertain the virulence of the RVVs derived from the attenuated VVs in more sensitive hosts, rabbits were chosen.
To estimate the intradermal replication of the RVVs and parental VVs, we scored the virus titer that produced a pox lesion 1.0 cm in diameter after inoculation by the intradermal route (Fig. 4) . Although inactivation of the HA gene of all the RVVs increased the erythema diameter dose, the extent of attenuation was the most extensive in the case of WR RVV, among the three RVVs. However, WR-proenvl still produced the largest pox lesion.
To examine multiplication of these RVVs in brain, 106.8
TCID50 of all the RVVs and VVs were inoculated by the i.c.
route, and development of clinical signs was examined (Table 5 ). This is the standard condition adopted to assess the neurovirulence of VV in rabbits when vaccines against smallpox were developed (9 To examine the neurovirulence more directly, a histological survey was performed ( Fig. 5 and Table 6 ). By this assay, we did not find significant differences in virulence between the RVVs and their corresponding parental VVs. However, neurovirulence of WR, LO-1, and LC16mO was confirmed to decrease in this order.
To quantitate further the multiplication capability of the RVVs and VVs in brain, a direct comparison of virus infectivity in the brain was carried out. LC16mO showed the most reduced capability to grow in brain, LO-1 was intermediate, and WR had the highest ability (Fig. 6) . The inactivation of the HA gene slightly reduced the multiplication capability of WR in brain, but its effect was not apparent in LC16mO and somewhat increased in that of LO-1. The thymidine kinase-negative (TK-) WR mutant grew in the brain as well as did the wild-type WR, although decreased neurovirulence of RVVs in mice has been reported (2).
DISCUSSION
We constructed RVVs expressing HTLV-I env proteins, using attenuated VVs as vectors. Three RVVs derived from different VV strains synthesized similar amounts of env proteins in vitro but had different capabilities to elicit antienv antibodies, well correlated with their ability to induce anti-VV antibodies. This suggests that the capacity of various VV strains to induce anti-HTLV-I antibody in vivo may be affected by their growth rates in rabbits.
Strain LC16mO grows relatively well intradermally, in contrast to its poor replication ability in CNS (9) . The RVV derived from LC16mO still retained these properties: it The RVV expressing hepatitis B surface antigen is reported to elicit a high titer of anti-hepatitis B antibody in rabbits (24) , but not in chimpanzees, despite its successful protection upon challenge with hepatitis B virus (17) . These results may be interpreted to indicate that a larger amount of antigen is required to induce a high titer of antibody in chimpanzees or in humans immunized with the RVV. To express the foreign gene at a higher level, we cloned and determined the nucleotide sequence of the putative promoter region of the A-type inclusion body (8) . Several foreign genes placed downstream of this promoter were demonstrated to be expressed much more efficiently as compared with the p7.5 promoter, the most frequently used promoter (data not shown) (3). The attenuated VV in combination with the stronger promoter may contribute to developing a more efficient and safer vaccine.
The VV thymidine kinase (TK) and HA loci were chosen as sites of insertion for foreign DNA, primarily because they provide efficient methods for selecting infectious recombinants (15, 19, 20) . B. Moss's group has reported that inactivation of the TK and HA genes led to attenuation of the WR strain (2, 7). We confirmed these findings and extended them to the LC16mO and LO-1 strains by using rabbits and mice. The extent of attenuation of LC16mO and LO-1 led by inactivation of the HA gene was much less than that of WR and depended on the host used. Recalling that LC16mO has a lower neurovirulence than the LO strain, which has been extensively used for smallpox vaccination (9), further attenuation of the former should be reconsidered from the viewpoint of its immunogenicity as described above. In this context, the site whose inactivation leads to no more attenuation of VV may be useful in some cases.
It is quite interesting to compare LC16mO, LO-1, and their RVVs in light of their multiplication capability in the CNS and other organs including skin. Induction of higher titers of anti-HTLV-I and anti-VV antibodies by LC16mO and its RVV than those by LO-1 and its RVV suggests that LC16mO and mO-proenv replicate in rabbits better than do LO-1 and LO-proenv. The similar size of pox lesions induced by LC16mO and LO-1 series may reflect the similar ability of these viruses to grow in the skin. By contrast, the fact that LO-1 and LO-proenv RVVs had a higher neurovirulence and that they were recovered from rabbit brain at higher titers than LC16mO and mO-proenv indicates that LO-1 grows better in the CNS than does LC16mO. These results suggest that the gene(s) which is responsible for the multiplication abilities of VV in the CNS may be different from the gene(s) controlling the growth of VV in other organs. In this regard, it is interesting that the HindlIl DNA fragment of Lister strain is involved in the capacity of virus dissemination in vitro but not in temperature sensitivity or neurovirulence in rabbits (27) . The gene(s) that controls replication ability in the CNS remains to be determined.
